A revalidation study of viral clearance in the purification of monoclonal antibody CB.Hep-1

BioPharm International

Volumn 20, Issue 1, 2007, Pages 46-55

  Del Rosario Alemán, María ^b   Noa, Enrique ^c   Tamayo, Andrés ^b   Dubed, Marta ^c   Padilla, Sigifredo ^b   Alvarez, Giselle ^c   Geada, Déborah ^d   Dorta, Lamay ^b   Navea, Leonor ^d   González, Tatiana ^b   Reyes, Biunayki ^b   Fernández, Eutimio Gustavo ^e   Valdés, Rodolfo ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b CGEB   (Cuba)

^c National Reference Center for AIDS   (Cuba)

^d Tobacco Research Institute   (Cuba)

^e Center for Engineering and Chemical Researches   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; HYDROCHLORIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CB HEP 1; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ARTICLE; DRUG PURIFICATION; HERPES SIMPLEX VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1; MATHEMATICAL ANALYSIS; PARVOVIRUS; POLIOMYELITIS VIRUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; SCALE UP; VIRUS INACTIVATION;

EID: 33846414322     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Quiñones Y, Agraz A, Silva A, Padrón G, Mella C, Díaz R, et al. High purity recombinant human alpha-2 interferon free from oligomeric forms in E. Coli. Highlights Modern Biochem 1989; 2:1237-1246.
2. Stum DC, Thienpont M, Collen D. Isolation y characterization of single chain urokinase (prourokinase) and urokinasa-inhibitor complex. J. Biological Chemistry 1986; 261:1267-1273.
3. Harbour C, Woodhouse G. Viral contamination of monoclonal antibody preparations: potential problems and possible solutions. Cytotechnology 1990; 4:3-12.
4. Hart CA. Transmissible spongioform encephalopathies. J Med Microbiol. 1995; 42:153-155.
5. Borovec S, Broumis C, Adcock W, Fang R, Uren E. Inactivation kinetics of model and relevant bloodborne viruses by treatment with sodium hydroxide and heat. Biologicals 1998; 26, 3:237-244.
6. Committee for Proprietary Medicinal Products. EEC regulatory document, note for guidance: Validation of viral removal and inactivation procedure. Biological, 1991; 19:247-25.
7. Darling JA, Spaltro JJ. Process validation for virus removal. Biopharm 1996; 10:42-50.
8. Minor P. Adventitious viral agents in biological product. Develop. Biol. Standard 1989; 70:173-179.
9. FDA. Guideline on general principles of process validation. CDER. Bethesda Md: 1978 May.
10. Juran JM, Gryna MF, editors Juran's quality control handbook, 4th ed. New York: McGraw-Hill; 1988.
11. Sofer G. Validation: ensuring the accuracy of scaled-down chromatography method. Biopharm 1998; 10:51-54.
12. Fontirrochi G, Dueñas M, Fernández E, Fuentes P Pérez M, Mainet D, et al., A mouse hybridoma cell line secreting IgG and IgM with specificity for the Hepatitis B surface antigen virus requirements for biological substances. Biotecnología Aplicada 1993; 10:25-30.
13. Hardy E, Martínez E, Diago D, Díaz R, González D, Herrera L. Large scale production of recombinant Hepatitis B surface antigen from Pichia pastoris. J. Biotechnology 2000; 17:155-157.
14. Fernández ME, Díaz T, Galván A, Valdés R, González E, Ayala M, et al. Antigen recognition characteristics and comparative performance in immunoaffinity purification of two monoclonal antibodies specific for the Hepatitis B virus surface antigen. J Biotechnol. 1997; 56:69-80.
15. Valdés R, Ibarra N, Ruibal I, Bederraín A, Noa E, Herrera N, et al. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses. J. Biotechnology 2002; 96:251-258.
16. Valdés R, Díaz T, Nieto A, García C, Pérez M, García J, Quiñones Y. Sendai virus removal and inactivation during monoclonal antibody purification. Biotecnología Aplicada 2005; 12 (2):115-119.
17. Kelly DB, Jeening P, Wright R, Briaco C. Demonstrating the process robustness for Chromatographie purification of a recombinant protein. Biopharm 1997; 10:36-45.
18. Berthold W, Walter J, Werz W. Experimental approaches to guarantee minimal risk of potential virus in purified monoclonal antibodies. Cytotechnology 1992; 9:189-201.
19. Laemmli. UK. Cleavage of structural proteins during the assembly by bacteriophage T 4. Nature 1970; 270:680-685.
20. Reed. LJ, Müench H. A simple method of estimating fifty per cent endpoints. Amer. J. Hyg. 1938; 27:493-487.
21. White EM, Grun BJ, Sur C-S, Sito FA. Process validation for virus removal and inactivation. BioPharm 1991; 4(5):30-33.
22. Willkommen H. Safety issue with recombinant technologies, assessment of clinical trial material. Bioprocess Int. Prague, 2006. Feb 21.
23. Cameron R, Davies J, Adcock W, Mac Gregor A, Bargord RJ, Cossart Y, Harcour C. The removal of model virus, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatography procedures. Biologicals 1997; 25:391-401.